Pattern of a Serum Biomarker Panel in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients – A Single Center Study From Low/Middle Income Country
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Mona Fakhry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Biomarkers, Graft vs Host Disease. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Allogenic hematopoietic stem cell transplantation is compromised by transplant‐related morbidity and mortality, particularly acute graft‐versus‐host disease (aGVHD). Early diagnosis or prediction of aGVHD is crucial for improving treatment outcomes. This study aimed to explore the utility of a biomarker panel for predicting and diagnosing aGVHD, as well as correlating biomarkers with aGVHD severity and response to treatment.
Methods
In this prospective study of 83 pediatric patients undergoing allogeneic HSCT, patterns of seven biomarkers were followed starting from the day of stem cell infusion up to day 90 post‐transplant.
Results
Patients with aGVHD exhibited significantly higher levels of IL‐2Rα, IL‐6, IL‐8, and HGF at the onset of aGVHD. Furthermore, patients with refractory aGVHD demonstrated elevated levels of HGF on day 28 post‐transplant. In aGVHD patients, the biomarkers exhibited a distinct pattern. With the exception of IL‐6, all biomarkers significantly increased at the onset of aGVHD. Following treatment, most biomarker levels decreased, except IL‐6, IL‐8, and HGF, which remained elevated 28 days post therapy initiation. These three biomarkers were also significantly higher in steroid‐refractory patients.
Conclusion
In summary, IL‐2Rα, IL‐6, IL‐8, and HGF show potential for aiding in the diagnosis of aGVHD. Additionally, HGF, IL‐6, and IL‐8 levels may serve as predictors of response to steroid therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
- Department of Pediatric Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
- Virology and Immunology Department, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
- Virology and Immunology Department, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
ORCID-Profile: Mona Fakhry, Ahmed Elhemaly, Mahmoud Hammad, Ghada M Al-Toukhy, Alaa Elhaddad
Zitieren
APA
Fakhry, M., Elhemaly, A., Hammad, M., Al-Toukhy, G. M., Mansour, M. T., & Elhaddad, A. (2025). Pattern of a Serum Biomarker Panel in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients – A Single Center Study From Low/Middle Income Country. Pediatric Transplantation. https://doi.org/10.1111/petr.70211
Vancouver
Fakhry M, Elhemaly A, Hammad M, Al-Toukhy GM, Mansour MT, Elhaddad A. Pattern of a Serum Biomarker Panel in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients – A Single Center Study From Low/Middle Income Country. Pediatric Transplantation. 2025. doi:10.1111/petr.70211
BibTeX
@article{Fakhry2025,
author = {Fakhry, Mona and Elhemaly, Ahmed and Hammad, Mahmoud and Al-Toukhy, Ghada M and Mansour, M T and Elhaddad, Alaa},
title = {Pattern of a Serum Biomarker Panel in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients – A Single Center Study From Low/Middle Income Country},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70211}
}
EUVIMED